-
X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
Jun 12, 2019, 13:49 PM by Michael CroftCAMBRIDGE, MA, UNITED STATES - Jun 12, 0019 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and Invitae Corporation (NYSE: NVTA), a leader in medical genetics, today announced a partnership to provide genetic testing at no cost to patients through its collaborative PATH4WARD programFull story -
Certara’s Simcyp PBPK Modeling and Simulation Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug
Jun 12, 2019, 08:18 AM by Michael CroftPRINCETON, NJ - Jun 12, 2019 - Certara® the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that its Simcyp® physiologically-based pharmacokinetic (PBPK) modeling and simulation technology was used to demonstrate bioequivalence (BE) for the US Food and Drug Administration (FDA) approval of a complex generic drug on the agencys abbreviated new drug application (ANDA) pathwayFull story -
Amsterdam University Medical Center wins MR Solutions’ newly launched Image of the Year Award
Jun 11, 2019, 12:52 PM by Michael CroftGUILDFORD, UNITED KINGDOM - Jun 11, 2019 - The Amsterdam University Medical Center has won MR Solutions Image of the Year 2019 award for the best molecular research imageFull story -
Quanticate Expands Presence in North America with New Toronto Office
Jun 11, 2019, 04:04 AM by Michael CroftTORONTO, ON, CANADA - Jun 11, 2019 - Quanticate, a leading global data-focused clinical research organisation (CRO), has announced plans to expand its presence in North America with the opening of a new office in TorontoFull story -
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore
Jun 10, 2019, 13:13 PM by Michael CroftNEW YORK, NY, UNITED STATES - Jun 10, 2019 - Calliditas Therapeutics AB ("Calliditas") and Everest Medicines II Limited ("Everest Medicines") announced today that they have entered into a license agreement to develop and commercialize Calliditas' leading drug candidateNefeconin Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy (IgAN)xFull story -
Golden Helix Releases Cancer Add-On To VSClinical
Jun 10, 2019, 11:35 AM by Michael CroftFull storyBio-IT World News Brief | Golden Helix has announced a cancer addition to their clinical analytics product, VSClinical. This new capability will guide clinicians through the clinical assessment of somatic variants, adding workflows modeled off the guidelines issued by the Association of Molecular Pathologists.
-
Certara Scientists to Highlight Model-informed Drug Development, PBPK, MBMA and Quantitative Systems Pharmacology Progress at PAGE 2019
Jun 10, 2019, 10:23 AM by Michael CroftPRINCETON, NJ - Jun 10, 2019 - Certara® the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that its scientists will participate in 28 sessions at the Population Approach Group in Europe (PAGE) 2019 Annual MeetingFull story -
Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research
Jun 10, 2019, 09:56 AM by Michael CroftPHILADELPHIA, PA, UNITED STATES - Jun 10, 2019 - CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealthFull story -
Organoids And Their Impact On Pre-Clinical Drug Discovery
Jun 7, 2019, 12:40 PM by Michael CroftFull storyBio-IT World | Pharmaceutical companies are looking for ways to save time and money in the drug discovery process. If there was a way to determine a therapy's impact in the pre-clinical process, researchers would have a better understanding of where to focus their efforts. This is where organoids come in.
-
Aalto Bio Reagents Launches World's First Commercially Available Venezuela Equine Encephalitis Virus (VEEV) Protein
Jun 7, 2019, 07:01 AM by Michael CroftDUBLIN, IRELAND - Jun 7, 2019 - On the occasion of the 11th International Global Virus Network meeting, Aalto Bio Reagents launches the first commercially available protein for the detection and diagnosis of Venezuela Equine Encephalitis NSP2 TC83Full story -
Rho Experts Discuss the Importance of Early Patient Involvement in Clinical Trial Design in Free Webinar
Jun 5, 2019, 13:54 PM by Michael CroftDURHAM, NC - Jun 6, 2019 - Rho Experts Discuss the Importance of Early Patient Involvement inClinical Trial Design in Free Webinar WHAT: Patient-centricity gets a lot of buzz as an essential aspect in research, drug development and disease managementFull story -
The Future Of Blockchain: The Use Cases Set To Reshape Life Sciences
Jun 5, 2019, 07:50 AM by Michael CroftFull storyBio-IT World Contributed Commentary | Ever since blockchain burst onto the scene a decade ago, people have continually found new—and sometimes odd—applications for the technology. Yet when it comes to the life sciences, a lack of practical applications has resulted in blockchain being considered a "hammer in search of a nail."
-
BINDING SITE OFFERS TICK-BORNE ENCEPHALITIS (TBE) ANTIGENS FOR RESEARCH & IVD MANUFACTURING APPLICATIONS
Jun 4, 2019, 11:01 AM by Michael CroftSAN DIEGO, CA - Jun 4, 2019 - ~~San Diego, CA . . . . BINDING SITEs IMMUNOLOGICALS GROUP is pleased to announce the addition of two (2) new native Tick-Borne Encephalitis (TBE) viral antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applicationsFull story -
Sterling announces pilot plant facility expansion is operational
Jun 4, 2019, 09:10 AM by Michael CroftNEWCASTLE, UK - Jun 4, 2019 - Contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions has announced the expansion of its pilot plant facility is now operational at its UK site following a £6million investment last yearFull story -
2 Chinese Babies With Edited Genes May Face Higher Risk Of Premature Death
Jun 3, 2019, 12:40 PM by Michael CroftFull storyNPR.org | There are new concerns about the world's first genetically modified babies. It appears that the genetic variation a Chinese scientist was trying to recreate when he edited twin girls' DNA may be more harmful than helpful to health overall, according to a study published Monday.
-
BioIVT HEPATOPAC® Meeting to Highlight Advances in Drug Discovery Research
Jun 3, 2019, 10:49 AM by Michael CroftWESTBURY, NY - Jun 3, 2019 - BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a HEPATOPAC Meeting at the AC Hotel by Marriott, San Francisco Airport/Oyster Point Waterfront on June 7Full story -
PerkinElmer Joins Accenture's Open Partner Ecosystem
Jun 3, 2019, 09:55 AM by Michael CroftFull storyBio-IT World | PerkinElmer has signed on to Accenture's open partner ecosystem and will integrate its big data technology and content into the cloud-based platform's wider efforts in drug discovery and research.
-
BOC Sciences to Reorganize Custom Synthesis for the Pharmaceutical Industry
Jun 2, 2019, 22:09 PM by Michael CroftSHIRLEY, LONG ISLAND CITY, NY, UNITED STATES - Jun 3, 2019 - The New York-based chemical vendor BOC Sciences announces to reorganize its custom synthesis for the pharmaceutical industryFull story -
Grail Outlines Its Plans For A Blood Test To Detect Cancer
May 31, 2019, 10:00 AM by Michael CroftFull storySTAT | Could a blood test detect cancer in healthy people? Grail, a Menlo Park, Calif.-based company, has raised $1.6 billion in venture capital to prove the answer is yes.
-
MR Solutions’ multi-modality, cryogen free technology is recognised as the norm at the ISMRM meeting in Montreal
May 30, 2019, 10:52 AM by Michael CroftGUILDFORD, UNITED KINGDOM - May 24, 2019 - MR Solutions high field simultaneous PET-MR systems and large bore, 7T cryogen free MRI technology were seen to be game-changers by leading molecular imaging researchers at the 27th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM)[i], in Montreal last weekFull story